PPLPHARMA — Piramal Pharma Share Price
0.000.00%
Last trade - 00:00- IN₹283.81bn
- IN₹327.14bn
- IN₹81.71bn
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 61.05 | ||
| PEG Ratio (f) | 0.88 | ||
| EPS Growth (f) | 224.06% | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 3.61 | ||
| Price to Tang. Book | 7.66 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 3.19 | ||
| EV to EBITDA | 17.39 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 11.21% | ||
| Return on Equity | 0.5% | ||
| Operating Margin | 12.54% | ||
Financial Summary
| Year End 31st Mar | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | IN₹m | n/a | 29,388.1 | 65,591 | 70,815.5 | 81,711.6 | 92,866.73 | 104,672.22 | 40.62% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | -31.66 | n/a | n/a | +137.82 | +223.22 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Piramal Pharma Limited is a global pharmaceutical company, which offers a portfolio of differentiated pharma products across a domestic and global distribution network. It operates approximately 17 development and manufacturing facilities across India, UK/Europe, and North America. It has a commercial presence in over 100 countries. The Company operates under three business verticals: Piramal Pharma Solutions (PPS), an integrated Contract Development and Manufacturing Organization (CDMO); Piramal Critical Care (PCC), a Complex Hospital Generics (CHG) business; and India Consumer Healthcare (ICH) business, selling over-the-counter (OTC) products. PPS caters to both drug substances - Active Pharmaceutical Ingredients (APIs), and drug products (formulations). PCC's complex hospital product portfolio comprises over 35 hospital-focused products in the areas of inhalation anesthesia, injectable anesthesia and pain management, intrathecal therapy, and other generic and specialty products.
Directors
- Last Annual
- March 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- March 4th, 2020
- Public Since
- October 19th, 2022
- No. of Shareholders
- 307,240
- No. of Employees
- 6,719
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- National Stock Exchange of India
- Shares in Issue
- 1,321,193,778
- Address
- Gr. Flr.,Piramal Ananta, MUMBAI, 400070
- Web
- https://www.piramal.com/businesses/piramal-pharma/
- Phone
- +91 223802300
- Auditors
- Deloitte Haskins & Sells LLP
Upcoming Events for PPLPHARMA
Q1 2026 Piramal Pharma Ltd Earnings Release
Similar to PPLPHARMA
Aarey Drugs and Pharmaceuticals
National Stock Exchange of India
Aarti Drugs
National Stock Exchange of India
Aarti Pharmalabs
National Stock Exchange of India
Abbott India
National Stock Exchange of India
Accent Microcell
National Stock Exchange of India
FAQ
What is the Piramal Pharma share price?
As of Today at 22:39 UTC, shares in Piramal Pharma are trading at IN₹216.25. This share price information is delayed by 15 minutes.
How has the Piramal Pharma share price performed this year?
Shares in Piramal Pharma last closed at IN₹216.25 and the price had moved by +52.34% over the past 365 days. In terms of relative price strength the Piramal Pharma share price has outperformed the S&P BSE 100 Index by +43.51% over the past year.
What are the analyst and broker recommendations for Piramal Pharma?
The overall consensus recommendation for Piramal Pharma is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Piramal Pharma dividend yield?
The Piramal Pharma dividend yield is 0.05% based on the trailing twelve month period.
Does Piramal Pharma pay a dividend?
Last year, Piramal Pharma paid a total dividend of IN₹0.11, and it currently has a trailing dividend yield of 0.05%. We do not have any data on when Piramal Pharma is to next pay dividends.
When does Piramal Pharma next pay dividends?
We do not have data on when Piramal Pharma is to next pay dividends. The historic dividend yield on Piramal Pharma shares is currently 0.05%.
How do I buy Piramal Pharma shares?
To buy shares in Piramal Pharma you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Piramal Pharma?
As of the previous close price of IN₹216.25, shares in Piramal Pharma had a market capitalisation of IN₹283.81bn.
Where are Piramal Pharma shares listed?
Here are the trading details for Piramal Pharma:
- Country of listing: India
- Exchange: NSI
- Ticker Symbol: PPLPHARMA
What kind of share is Piramal Pharma?
Based on an overall assessment of its quality, value and momentum Piramal Pharma is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Piramal Pharma share price forecast for 2025?
The analyst consensus target price for shares in Piramal Pharma is IN₹292.51. That is 35.26% above the last closing price of IN₹216.25.
Analysts covering Piramal Pharma currently have a consensus Earnings Per Share (EPS) forecast of IN₹1.09 for the next financial year.
Find out moreWhat is the trend in the Piramal Pharma share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Piramal Pharma. Over the past six months, its share price has underperformed the S&P BSE 100 Index by -9.66%.
As of the last closing price of IN₹216.25, shares in Piramal Pharma were trading -2.02% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Piramal Pharma PE Ratio?
The Piramal Pharma PE ratio based on its reported earnings over the past 12 months is 61.05. The shares last closed at IN₹216.25.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Piramal Pharma?
We do not have data on Piramal Pharma's directors